A Comparison of an Australian Observational Longitudinal Alzheimer's Disease Cohort to Community-Based Australian Data
- PMID: 39213065
- PMCID: PMC11491991
- DOI: 10.3233/JAD-240241
A Comparison of an Australian Observational Longitudinal Alzheimer's Disease Cohort to Community-Based Australian Data
Abstract
Background: Observational Alzheimer's disease (AD) cohorts including the Australian, Biomarkers, Imaging and Lifestyle (AIBL) Study have enhanced our understanding of AD. The generalizability of findings from AIBL to the general population has yet to be studied.
Objective: We aimed to compare characteristics of people with AD dementia in AIBL to 1) the general population of older Australians using pharmacological treatment for AD dementia, and to 2) the general population of older Australians who self-reported a diagnosis of dementia.
Methods: Descriptive study comparing people aged 65 years of over (1) in AIBL that had a diagnosis of AD dementia, (2) dispensed with pharmacological treatment for AD in Australia in 2021 linked to the Australian census in 2021 (refer to as PBS/census), (3) self-reported a diagnosis of dementia in the 2021 Australian census (refer to as dementia/census). Baseline characteristics included age, sex, highest education attainment, primary language, and medical co-morbidities.
Results: Participants in AIBL were younger, had more years of education, and had a lower culturally and linguistically diverse (CALD) population compared to the PBS/census cohort and dementia/census cohort (mean age±standard deviation - AIBL 79±7 years, PBS/census 81±7, p < 0.001, dementia/census 83±8, p < 0.001; greater than 12 years of education AIBL 40%, PBS/census 35%, p = 0.020, dementia/census 29%, p < 0.001; CALD - AIBL 3%, PBS/census 20%, p < 0.001, dementia/census 22%, p < 0.001).
Conclusions: Our findings suggest that care should be taken regarding the generalizability of AIBL in CALD populations and the interpretation of results on the natural history of AD.
Keywords: Alzheimer’s disease; Australian Biomarkers Imaging and Lifestyle study; Australian census; culturally and linguistically diverse; dementia; generalizability.
Conflict of interest statement
Colin Masters is an Editorial Board Member of this journal but was not involved in the peer-review process nor had access to any information regarding its peer-review. All other authors have no conflicts of interest to report.
Similar articles
-
Elucidating the Link Between Anxiety/Depression and Alzheimer's Dementia in the Australian Imaging Biomarkers and Lifestyle (AIBL) Study.J Epidemiol Glob Health. 2024 Sep;14(3):1130-1141. doi: 10.1007/s44197-024-00266-w. Epub 2024 Jun 19. J Epidemiol Glob Health. 2024. PMID: 38896210 Free PMC article.
-
Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.J Prev Alzheimers Dis. 2019;6(4):248-255. doi: 10.14283/jpad.2019.25. J Prev Alzheimers Dis. 2019. PMID: 31686097
-
Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative.Alzheimers Dement. 2010 May;6(3):291-6. doi: 10.1016/j.jalz.2010.03.009. Alzheimers Dement. 2010. PMID: 20451879
-
Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.Int Rev Psychiatry. 2013 Dec;25(6):699-710. doi: 10.3109/09540261.2013.870136. Int Rev Psychiatry. 2013. PMID: 24423223 Review.
-
Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney.Alzheimers Dement. 2022 Jan;18(1):178-190. doi: 10.1002/alz.12380. Epub 2021 May 31. Alzheimers Dement. 2022. PMID: 34058063 Free PMC article. Review.
Cited by
-
Development and validation of the Florey Dementia Risk Score web-based tool to screen for Alzheimer's disease in primary care.EClinicalMedicine. 2024 Sep 17;76:102834. doi: 10.1016/j.eclinm.2024.102834. eCollection 2024 Oct. EClinicalMedicine. 2024. PMID: 39328810 Free PMC article.
-
Development and validation of a model to predict the progression of Alzheimer's disease.Age Ageing. 2025 Jul 1;54(7):afaf198. doi: 10.1093/ageing/afaf198. Age Ageing. 2025. PMID: 40705053 Free PMC article.
References
-
- Dubois B, Feldman HH, Jacova C, et al.. Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol 2014; 13: 614–629. - PubMed
-
- Villemagne VL, Burnham S, Bourgeat P, et al.. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: A prospective cohort study. Lancet Neurol 2013; 12: 357–367. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical